The Federal Trade Commission is challenging hundreds of pharmaceutical patent listings in an effort to smooth the path to more affordable alternatives to brand-name drugs—including blockbusters ...
The agency has stepped up its campaign against drugmakers' improper listing of patents in the FDA's Orange Book, which it ...
The U.S. Federal Trade Commission (FTC) is not done with its crackdown on what it views as improper listing of patents with the FDA. After an initial round of challenges launched in November ...
The move targets over 300 listings for 20 branded products from companies such as AstraZeneca, Novo Nordisk, and GSK that the agency said inhibits the generic drug market. The Federal Trade Commission ...
The warning letters don't specify how the drugmakers are flouting patent regulations, or what criteria the FTC uses to make that determination. The Federal Trade Commission on Tuesday challenged ...
After an FTC challenge, companies have 30 days to withdraw or amend the patent or show it is valid. Some have already backed down. "We've had some significant wins," Garden-Monheit said.
Boehringer Ingelheim, one of 10 companies sent a warning letter by the FTC disputing the accuracy of patent listings in the ...
Biden was joined by FTC Chair Lina Khan and Consumer Financial Protection Bureau Director Rohit Chopra. The new FTC rule would require corporations to include all mandatory fees when communicating ...
WASHINGTON (CN) — The Federal Trade Commission filed a complaint Thursday to stop online tech support scams that bilk tens of millions of dollars from consumers, particularly older people. Reimage ...
The Federal Trade Commission is seemingly seeking to clear the path for generic versions of the weight loss drug Ozempic — but there will be a long road ahead before cheaper versions of the injectable ...